Fig. 2: Development and characterization of CDH17 x GUCY2C BsAbs. | Cell Death Discovery

Fig. 2: Development and characterization of CDH17 x GUCY2C BsAbs.

From: Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer

Fig. 2

A Structure diagram of six different CDH17 x GUCY2C BsAb formats. Knob-into-hole and crossmab technologies are used respectively to prevent mismatching of heavy and light chains in format BsAb 3 and BsAb 4. B The binding activities of CDH17 x GUCY2C BsAbs were analyzed in SW1463 and LS1034 cell lines at a concentration of 1 μg/mL. The CDH17 and GUCY2C monoclonal antibodies were used as controls. C The internalization activities of CDH17 x GUCY2C BsAbs were analyzed in SW1463 and LS1034 cell lines at a concentration of 1 μg/mL. The CDH17 and GUCY2C monoclonal antibodies were used as controls.

Back to article page